Anti-TNF therapy using etanercept suppresses degenerative and inflammatory changes in skeletal muscle of older SJL/J mice

Experimental and Molecular Pathology

Volumn 90, Issue 3, 2011, Pages 264-270

  Nemoto, Hiroshi ^a   Konno, Shingo ^a   Sugimoto, Hideki ^a   Nakazora, Hiroshi ^a   Nomoto, Nobuatsu ^a   Murata, Mayumi ^a   Kitazono, Hisao ^a   Fujioka, Toshiki ^a  

^a TOHO UNIVERSITY   (Japan)

Author keywords

Degeneration; Dysferlinopathy; Etanercept; Inflammation; SJL J mice; TNF

Indexed keywords

ETANERCEPT; TUMOR NECROSIS FACTOR;

ADIPOCYTE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; FIBROSIS; INFLAMMATION; MOUSE; MUSCLE FIBRIL; MUSCLE NECROSIS; NONHUMAN; PROTEIN FUNCTION; SKELETAL MUSCLE;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DISEASE MODELS, ANIMAL; IMMUNOGLOBULIN G; INFLAMMATION; MEMBRANE PROTEINS; MICE; MICE, KNOCKOUT; MUSCLE, SKELETAL; MUSCULAR DYSTROPHIES, LIMB-GIRDLE; RECEPTORS, TUMOR NECROSIS FACTOR; SURVIVAL RATE; TUMOR NECROSIS FACTOR-ALPHA;

MUS;

EID: 79952076124     PISSN: 00144800     EISSN: 10960945     Source Type: Journal    
DOI: 10.1016/j.yexmp.2011.02.003     Document Type: Article

References (47)

1. Bansal D., et al. Defective membrane repair in dysferlin-deficient muscular dystrophy. Nature 2003, 423:168-172.
2. Bernard C.C., Carnegie P.R. Experimental autoimmune encephalomyelitis in mice. Immunologic response to mouse spinal cord and myelin basic proteins. J. Immunol. 1975, 114:1537-1540.
3. Bittner R.E., et al. Dysferlin deletion in SJL mice (SJL-Dysf) defines a natural model for limb girdle muscular dystrophy 2B. Nat. Genet. 1999, 23:141-142.
4. Bortolotto S.K., et al. Mast cells play a pivotal role in ischaemia reperfusion injury to skeletal muscles. Lab. Invest. 2004, 84:1103-1111.
5. Breedveld F.C., et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2006, 54:26-37.
6. Cheung E.V., Tidball J.G. Administration of the non-steroidal anti-inflammatory drug ibuprofen increases macrophage concentrations but reduces necrosis during modified muscle use. Inflamm. Res. 2003, 52:170-176.
7. Collins R.A., Grounds M.D. The role of tumor necrosis factor-alpha (TNF-alpha) in skeletal muscle regeneration. Studies in TNF-alpha(-/-) and TNF-alpha(-/-)/LT-alpha(-/-) mice. J. Histochem. Cytochem. 2001, 49:989-1001.
8. Confalonieri P., et al. Muscle inflammation and MHC class I up-regulation in muscular dystrophy with lack of dysferlin: an immunopathological study. J. Neuroimmunol. 2003, 142:130-136.
9. Coulton G.R., et al. The mdx mouse skeletal muscle myopathy: I. A histological, morphometric and biochemical investigation. Neuropathol. Appl. Neurobiol. 1988, 14:53-70.
10. Doherty K.R., McNally E.M. Repairing the tears: dysferlin in muscle membrane repair. Trends Mol. Med. 2003, 9:327-330.
11. Fanin M., Angelini C. Muscle pathology in dysferlin deficiency. Neuropathol. Appl. Neurobiol. 2002, 28:461-470.
12. Goldenberg M.M. Etanercept, a novel drug for the treatment of patients with severe, active rheumatoid arthritis. Clin. Ther. 1999, 21:75-87.
13. Grounds M.D., Torrisi J. Anti-TNFalpha (Remicade) therapy protects dystrophic skeletal muscle from necrosis. FASEB J. 2004, 18:676-682.
14. Guglieri M., Bushby K. Molecular treatments in Duchenne muscular dystrophy. Curr. Opin. Pharmacol. 2010, 10:331-337.
15. Hernández-Deviez D.J., et al. Caveolin regulates endocytosis of the muscle repair protein, dysferlin. J. Biol. Chem. 2008, 283:6476-6488.
16. Hodgetts S., et al. Reduced necrosis of dystrophic muscle by depletion of host neutrophils, or blocking TNFalpha function with Etanercept in mdx mice. Neuromuscul. Disord. 2006, 16:591-602.
17. Hoffman E.P., et al. Conservation of the Duchenne muscular dystrophy gene in mice and humans. Science 1987, 238:347-350.
18. Hoffman E.P., et al. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 1987, 51:919-928.
19. Hohlfeld R., et al. Necrotizing myopathy in SJL mice. Muscle Nerve 1988, 11:184-185.
20. Huang Y., et al. AHNAK, a novel component of the dysferlin protein complex, redistributes to the cytoplasm with dysferlin during skeletal muscle regeneration. FASEB J. 2007, 21:732-742.
21. Klareskog L., et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004, 363:675-681.
22. Kostek C.A., et al. Up-regulation of MHC class I expression accompanies but is not required for spontaneous myopathy in dysferlin-deficient SJL/J mice. Am. J. Pathol. 2002, 160:833-839.
23. Kuru S., et al. Expression of tumor necrosis factor-alpha in regenerating muscle fibers in inflammatory and non-inflammatory myopathies. Acta Neuropathol. 2003, 105:217-224.
24. Lennon N.J., et al. Dysferlin interacts with annexins A1 and A2 and mediates sarcolemmal wound-healing. J. Biol. Chem. 2003, 278:50466-50473.
25. Lerman S.P., et al. Properties of reticulum-cell sarcomas in SJL/J mice. I. Proliferative response to tumor cells of T-derived lymphoid cells from normal mice. Int. J. Cancer 1974, 14:808-816.
26. Li Y.P., et al. TNF-alpha acts via p38 MAPK to stimulate expression of the ubiquitin ligase atrogin1/MAFbx in skeletal muscle. FASEB J. 2005, 19:362-370.
27. Lipsky P.E., et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N. Engl. J. Med. 2000, 343:1594-1602.
28. Llovera M., et al. Anti-TNF treatment reverts increased muscle ubiquitin gene expression in tumour-bearing rats. Biochem. Biophys. Res. Commun. 1996, 221:653-655.
29. Mariette X., et al. Registries in rheumatoid arthritis and autoimmune diseases: data from the French registries. Rheumatology (Oxford) 2011, 50:222-229.
30. Matsubara S., et al. Experimental allergic myositis in SJL/J mice immunized with rabbit myosin B fraction: immunohistochemical analysis and transfer. Acta Neuropathol. 1993, 85:138-144.
31. Nagaraju K., et al. Dysferlin deficiency enhances monocyte phagocytosis: a model for the inflammatory onset of limb-girdle muscular dystrophy 2B. Am. J. Pathol. 2008, 172:774-785.
32. Nemoto H., et al. FK506 suppressed the inflammatory change of EAM in SJL/J mice. J. Neurol. Sci. 2001, 193:7-11.
33. Nemoto H., et al. Histological and immunohistological changes of the skeletal muscles in older SJL/J mice. Eur. Neurol. 2007, 57:19-25.
34. Nguyen H.X., Tidball J.G. Interactions between neutrophils and macrophages promote macrophage killing of rat muscle cells in vitro. J. Physiol. 2003, 547:125-132.
35. Pierno S., et al. Role of tumour necrosis factor alpha, but not of cyclo-oxygenase-2-derived eicosanoids, on functional and morphological indices of dystrophic progression in mdx mice: a pharmacological approach. Neuropathol. Appl. Neurobiol. 2007, 33:344-359.
36. Porreca E., et al. Haemostatic abnormalities, cardiac involvement and serum tumor necrosis factor levels in X-linked dystrophic patients. Thromb. Haemost. 1999, 81:543-546.
37. Radley H.G., Grounds M.D. Cromolyn administration (to block mast cell degranulation) reduces necrosis of dystrophic muscle in mdx mice. Neurobiol. Dis. 2006, 23:387-397.
38. Radley H.G., et al. Reduced muscle necrosis and long-term benefits in dystrophic mdx mice after cV1q (blockade of TNF) treatment. Neuromuscul. Disord. 2008, 18:227-238.
39. Roberts L., McColl G.J. Tumour necrosis factor inhibitors: risks and benefits in patients with rheumatoid arthritis. Intern. Med. J. 2004, 34:687-693.
40. Rosenberg N.L., et al. Experimental autoimmune myositis in SJL/J mice. Clin. Exp. Immunol. 1987, 68:117-219.
41. Spencer M.J., et al. Helper (CD4(+)) and cytotoxic (CD8(+)) T cells promote the pathology of dystrophin-deficient muscle. Clin. Immunol. 2001, 98:235-243.
42. Stewart C.E., et al. Multifaceted roles of TNF-alpha in myoblast destruction: a multitude of signal transduction pathways. J. Cell. Physiol. 2004, 198:237-247.
43. Suzuki N., et al. Expression profiling with progression of dystrophic change in dysferlin-deficient mice (SJL). Neurosci. Res. 2005, 52:47-60.
44. Tidball J.G. Inflammatory processes in muscle injury and repair. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2005, 288:345-353.
45. Vafiadaki E., et al. Cloning of the mouse dysferlin gene and genomic characterization of the SJL-Dysf mutation. NeuroReport 2001, 12:625-629.
46. Warren G.L., et al. Physiological role of tumor necrosis factor alpha in traumatic muscle injury. FASEB J. 2002, 16:1630-1632.
47. Weller A.H., et al. Spontaneous myopathy in the SJL/J mouse: pathology and strength loss. Muscle Nerve 1997, 20:72-82.